We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients

By LabMedica International staff writers
Posted on 01 Nov 2025

Lupus is an autoimmune disorder that causes the immune system to attack the body’s own tissues and organs. More...

Among the five million people living with lupus globally, nearly half develop lupus nephritis, a severe kidney inflammation that is a leading cause of death. Between 5% and 25% of patients with lupus nephritis die from kidney-related complications within five years of onset. Currently, monitoring kidney health relies on renal biopsies—painful, invasive procedures with risks of bleeding and infection, as well as subjectivity in interpretation. Now, monitoring kidney damage in lupus patients may soon become far less invasive.

A new study from the University of Houston (Houston, TX, USA) has found that urine samples can reveal the severity and progression of lupus nephritis—a major complication of systemic lupus erythematosus (SLE)—without requiring repeat renal biopsies. The discovery could transform disease management for millions worldwide. The new study aimed to identify noninvasive biomarkers capable of predicting kidney inflammation and scarring by analyzing urinary proteins through a large-scale proteomics approach.

Using 1,317 urine samples collected at the time of biopsy from patients with lupus nephritis, the researchers identified 57 proteins that were significantly elevated in individuals whose kidney tissue showed active damage. These elevated proteins were linked to microscopic signs such as vascular swelling, tissue necrosis, and clusters of injured cells—hallmarks of ongoing inflammation.

Further analysis revealed that some urinary proteins were also associated with chronic scarring, suggesting they could help clinicians distinguish between active disease and long-term damage. These findings, published in The Journal of Clinical Investigation, demonstrate that urine-based biomarkers could provide a reliable, repeatable, and noninvasive way to assess kidney disease activity and progression in lupus patients.

“Overall, the results indicate that by measuring certain proteins in urine, doctors might be able to tell how active or long-lasting someone’s lupus-related kidney disease is, and they could check kidney health without having to do another biopsy,” said Dr. Chandra Mohan, an international expert and pioneer in lupus research at the University of Houston.

Related Links:
University of Houston


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.